AZN - AstraZeneca PLC
| Previous Close | 45.41 |
| Open | 45.28 |
| Bid | 44.30 x 1800 |
| Ask | 44.70 x 800 |
| Day's Range | 44.50 - 45.67 |
| 52 Week Range | 35.30 - 45.69 |
| Volume | 3,743,273 |
| Avg. Volume | 3,014,154 |
| Market Cap | 114.428B |
| Beta (3Y Monthly) | 0.48 |
| PE Ratio (TTM) | 52.08 |
| EPS (TTM) | 0.86 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 1.40 (3.08%) |
| Ex-Dividend Date | 2019-08-08 |
| 1y Target Est | 46.14 |
- Simply Wall St.
We Think AstraZeneca (LON:AZN) Can Stay On Top Of Its Debt
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...
- Zacks
Pharma Stock Roundup: ABBV's Rinvoq Gets FDA Nod, BAYRY to Sell Animal Health Unit
FDA approves AbbVie's (ABBV) upadacitinib to be marketed as Rinvoq. Bayer (BAYRY) is set to divest its Animal Health unit to Elanco for $7.6 billion in a cash-and-stock deal.
- Zacks
Roche's Tecentriq Gets Japan's Nod for Small Cell Lung Cancer
Roche (RHHBY) gets approval for Tecentriq in Japan for extensive-stage SCLC.
- Zacks
AstraZeneca's Kidney Drug Roxadustat Gets Second Nod in China
AstraZeneca's (AZN) roxadustat gets a second marketing approval in China for treating anaemia caused by chronic kidney disease in non-dialysis-dependent patients.
- Benzinga
The Daily Biotech Pulse: ViiV's Long-Acting HIV Drug Meets Study Goal, Chinese Cheer For FibroGen, Retrophin Flunks Late-Stage Study
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Aug. 21) Apellis Pharmaceuticals Inc (NASDAQ: APLS ) Arrowhead ...
- Zacks
AstraZeneca's Imfinzi Fails in Stage IV Lung Cancer Study
AstraZeneca's (AZN) Imfinzi fails to improve overall survival in a study for previously treated stage IV non-small cell lung cancer (NSCLC) patients.
- Benzinga
AstraZeneca's Drug Combo To Treat Non-Small Cell Lung Cancer Stumbles In Late-Stage Study
AstraZeneca plc (NYSE: AZN ) faced a clinical setback in a study evaluating a combo drug regimen in non-small cell lung cancer, or NSCLC. What Happened AstraZeneca said a Phase 3 study dubbed NEPTUNE that ...
- Reuters
UPDATE 2-AstraZeneca Imfinzi combination fails advanced lung cancer study
A combination of AstraZeneca's lung cancer drug Imfinzi and an experimental treatment failed to extend the lives of patients with advanced non-small cell lung cancer (NSCLC) and high levels of gene mutations, the drugmaker said on Wednesday. The late-stage clinical trial was testing Imfinzi, chemically known as durvalumab, along with another treatment tremelimumab and compared the combination to platinum-based chemotherapy to treat patients whose cancer had spread beyond the lungs.
- Financial Times
AstraZeneca faces setback in lung cancer drug trial
AstraZeneca has disclosed a setback for one of its key cancer treatments, saying a trial involving immunotherapy drug Imfinzi was no more effective than regular chemotherapy at treating advanced lung cancer. for early stage lung cancer, and the Anglo Swedish drugmaker has been rolling out trials combining it with different immunotherapy drugs to assess its effectiveness at treating later stages of the disease. The theory is that combining two immunotherapy drugs together into one treatment could boost survival rates.
- Reuters
China adds 148 drugs to key insurance list - state media
BEIJING/SHANGHAI, Aug 20 (Reuters) - China on Tuesday added 148 drugs to its list of medicines covered by basic medical insurance schemes, part of a push to lower patients' out-of-pocket costs in one of the world's largest drug markets, state media reported. AstraZeneca's Kombiglyze and Merck & Co's Janumet diabetes treatments are among the drugs that will now be covered by national insurance, according to the updated list published by China's National Healthcare Security Administration. As it published the updated list of 2,643 drugs on its website on Tuesday, the healthcare administration said the adjustment was crucial to improving the efficient use of the country's medical insurance funds.
- Business Wire
FARXIGA Met Primary Endpoint in Landmark Phase III DAPA-HF Trial for the Treatment of Patients With Heart Failure
DAPA-HF is the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type 2 diabetes
- MarketWatch
Sainsbury continues climb from 30-year low as FTSE 100 edges higher
J Sainsbury on Tuesday continued its recovery from a 30-year low after data showed the supermarket chain was the best performer of the top four for the first time in nearly two years.
- Reuters
UPDATE 2-European shares end lower as Italy's political crisis weighs
European shares fell on Tuesday after two sessions of robust gains as optimism over hopes of stimulus in major economies waned and investors awaited more guidance from central banks. Concerns about Italy's government further dented sentiment, though Italian bond yields fell after Prime Minister Giuseppe Conte said he would resign, potentially paving the way for a new coalition government. Markets in Italy have been volatile since the leader of the League, Matteo Salvini, pulled support from his coalition arrangement with the 5-Star Movement on August 8.
- Reuters
European shares rise for third straight session
European shares rose for the third straight session on Tuesday, building on a recovery since late last week as British drugmaker AstraZeneca surged on results of a late-stage study. Shares of the drugmaker rose 1.5% after the company said its diabetes drug Farxiga met the main goal of the study for the treatment of patients with heart failure.
- Zacks
Pharma Stock Roundup: Pipeline/Regulatory Updates From JNJ, LLY, AZN, RHHBY
FDA approves Roche's (RHHBY) tumor-agnostic medicine, Rozlytrek, J&J's Sirturo for young TB patients.
- Zacks
AstraZeneca Calquence Gets FDA's Breakthrough Status for CLL
The Breakthrough Therapy Designation (BTD) to AstraZeneca's (AZN) Calquence is based on positive interim data from two phase III studies.
- Zacks
Roche Receives FDA Nod for Rozlytrek in ROS1-positive NSCLC
Roche's (RHHBY) lung cancer portfolio gets a boost with the approval of yet another drug, Rozlytrek, for metastatic NSCLC.
- Zacks
Agios Rides High on Tibsovo Sales Amid Acute Competition
Agios' (AGIO) wholly owned precision medicine Tibsovo is picking up sales since its approval and strong sequential growth delivered in Q2. Undue reliance on Celgene for royalties is a constant worry.
- Zacks
Merck's Cancer Immunotherapy Keytruda Continues to Aid Growth
Merck's (MRK) Keytruda is rapidly gaining strength as a key contributor to the company's top line. The Keytruda development program is also progressing well.
- Motley Fool
3 Healthcare Stocks at All-Time Highs: Are They Buys?
They're flying high right now. But are these three healthcare stocks smart picks?
- Business Wire
CALQUENCE® (acalabrutinib) Granted US Breakthrough Therapy Designation for Chronic Lymphocytic Leukemia
Designation based on positive results from two Phase III trials
- Business Wire
LYNPARZA® (olaparib) Phase III Paola-1 Trial Met Primary Endpoint as 1st-line Maintenance Treatment With Bevacizumab for Advanced Ovarian Cancer
AstraZeneca and Merck’s LYNPARZA when added to standard-of-care bevacizumab significantly increased the time women lived without disease progression or death
- Benzinga
AstraZeneca Success On Prostate Cancer Drug Lowers Enthusiasm For Clovis
Last week, AstraZeneca plc (NYSE: AZN) reported positive results for its prostrate cancer treatment Lynparza for patients with certain genetic profiles. Ahmad wrote in a note on Tuesday that AstraZeneca’s incremental success changes the game for Clovis.
- Zacks
Spectrum Pharma's (SPPI) Loss Narrows in Q2, Stock Rises
Spectrum Pharma (SPPI) beats bottom-line estimates in the second quarter.
- Reuters
No-deal Brexit could deepen Europe's shortage of medicines - experts
As the Oct. 31 deadline for Britain to leave the European Union approaches, health professionals are warning that shortages of some medicines could worsen in Europe in the event of a no-deal Brexit. Britain's food and drink lobby warned last week that the country would experience shortages of some fresh foods if there is a disorderly no-deal Brexit.
